Nadolol & Bendroflumethiazide – A Quick Reference
| Feature | Nadolol | Bendroflumethiazide |
|---|---|---|
| Drug class | Non‑selective β‑adrenergic blocker (β₁/β₂) | Thiazide‑class diuretic |
| Typical dose | 20–80 mg PO once daily (often 40 mg) | 2.5–25 mg PO once daily (often 2.5–5 mg) |
| Common indications | Hypertension, angina, tachyarrhythmias | Hypertension, edema (cardiac, renal, hepatic), hypertensive emergencies (with other agents) |
| Key pharmacodynamics | Blocks β‑receptors → ↓ heart rate, ↓ contractility, ↓ renin release → ↓ angiotensin II | Inhibits Na⁺/Cl⁻ reabsorption in distal tubule → ↑ urinary Na⁺/Cl⁻ → ↓ extracellular fluid → ↓ BP |
| Major side‑effects | Bradycardia, dizziness, fatigue, depression, sexual dysfunction, mask hypoglycaemia | Hypokalaemia, hyponatraemia, hyperuricaemia, hyperglycaemia, dehydration, gout flare |
| Contraindications | Severe asthma/COPD, second‑/third‑degree AV block, cardiogenic shock, sinus node dysfunction | Severe hyperkalaemia, anuria, severe renal impairment, pregnancy (avoid unless necessary) |
| Drug‑drug interactions | • + diuretics → additive BP ↓ & bradycardia risk
• + ACEI/ARB → ↑ hyperkalaemia
• + NSAIDs → ↓ diuretic efficacy
• + digoxin → ↑ digoxin levels | • + β‑blockers → additive BP ↓ and bradycardia
• + potassium‑sparing diuretics/ACEI/ARB → hyperkalaemia
• + alcohol → ↑ diuresis & hypotension
• + antidiabetics → altered glucose control |
| Monitoring | BP, HR, renal function, electrolytes (especially K⁺), signs of heart failure | BP, electrolytes (Na⁺, K⁺, Mg²⁺, Ca²⁺), renal function, uric acid, glucose, signs of dehydration |
---
Why Use Them Together?
Both drugs lower blood pressure but act through different mechanisms—β‑blockers reduce cardiac output and renin release, while thiazide diuretics decrease intravascular volume. Combining them is a common first‑line strategy for resistant hypertension or when a single agent does not achieve adequate control.
Key points for the clinician:
1. Start with low doses and titrate slowly to avoid orthostatic hypotension.
2. Monitor electrolytes—bendroflumethiazide increases potassium loss, while the β‑blocker may mask bradycardic symptoms.
3. Watch for drug‑drug synergy—especially if the patient is on ACEI/ARB or potassium‑sparing agents.
4. Consider the patient’s comorbidities: e.g., in heart failure, β‑blockers are protective; in gout, avoid diuretic‑induced hyperuricaemia.
---
Patient‑Facing Tips
| What to tell patients | Practical advice |
|---|---|
| Take at the same time each morning (usually with breakfast) to maintain steady blood levels. | Avoid late‑evening doses of bendroflumethiazide to reduce nighttime urinary frequency. |
| Watch for dizziness or fainting—stand up slowly, especially when first starting or increasing dose. | Keep a “low‑potassium” diet (avoid excess bananas, oranges, spinach, and potato chips) and consider potassium supplements if levels drop. |
| Avoid excessive alcohol—it can increase diuresis and lower BP further. | Stay hydrated; sip water regularly but not too much—balance fluid loss and intake. |
| Check your BP at home (if you can) and keep a log; share any sustained low readings or dizziness with your clinician. | |
| Report any swelling, shortness of breath, or chest pain—these could signal heart failure or severe hypotension. | |
| If you feel unusually tired or have mood changes (especially with β‑blockers), let your healthcare provider know. | |
---
Quick “Safety Net” Checklist
| Issue | How to Address |
|---|---|
| Hypokalaemia | Check K⁺ every 2–4 weeks initially, then 3–6 month intervals. Use K⁺ supplements or consider switching to a potassium‑conserving diuretic if persistent. |
| Hypertension still uncontrolled | Consider adding an ACEI, ARB, or calcium‑channel blocker, but watch for hyperkalaemia. |
| Gout flare | Avoid high‑purine foods, consider allopurinol if recurrent flares, monitor uric acid. |
| New‑onset depression or anxiety | β‑blockers can occasionally worsen mood; discuss with provider. |
| Pregnancy or breastfeeding | Both drugs are category C. Use only if benefits outweigh risks and after consulting a specialist. |
---
Bottom Line
- Nadolol is a reliable β‑blocker for hypertension, heart failure, and angina.
- Bendroflumethiazide is a milder diuretic useful for mild‑to‑moderate hypertension and edema.
- Combined therapy often provides superior BP control but requires vigilant monitoring of blood pressure, heart rate, and electrolytes.
- Patient education is critical—teach them to recognize symptoms of hypotension, dehydration, electrolyte imbalance, and to adhere to diet and medication timing.
If you’re considering starting or adjusting these medications, or if you have any specific concerns (e.g., kidney disease, gout, pregnancy), please discuss with your healthcare provider. They can tailor the regimen to your personal health profile and keep you